Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary

References

• Ferrannini E, Gastaldelli A, Iozzo P. Pathophysiology of prediabetes. Med Clin North Am. 2011;95:327–339.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787–835.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Mari A. β-Cell function in type 2 diabetes. Metabolism. 2014;63:1217–1227.
   PubMed Web of Science ®Google Scholar
• Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord. 2008;9:329–343.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Williams K, DeFronzo R, et al. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care. 2006;29:1613–1618.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29:1130–1139.
   PubMed Web of Science ®Google Scholar
• Townsend KL, Lorenzi MM, Widmaier EP. High-fat diet-induced changes in body mass and hypothalamic gene expression in wild-type and leptin-deficient mice. Endocrine. 2008;33:176–188.
   PubMed Web of Science ®Google Scholar
• Thaler JP, Schwartz MW. Minireview: inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology. 2010;151:4109–4115.
   PubMed Web of Science ®Google Scholar
• Chari M, Lam CKL, Lam TKT. Hypothalamic fatty acid sensing in the normal and disease states. In: Montmayeur JP, Le Coutre J, editors. Frontiers in neuroscience. Fat detection: taste, texture, and post ingestive effects. Boca Raton (FL): CRC Press; 2010. p. Ch20.
   Google Scholar
• Demuro G, Obici S. Central nervous system and control of endogenous glucose production. Curr Diab Rep. 2006;6:188–193.
   PubMedGoogle Scholar
• Martínez De Morentin PB, Varela L, Fernø J, et al. Hypothalamic lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 2010;1801:350–361.
   PubMed Web of Science ®Google Scholar
• Parlevliet ET, Coomans CP, Rensen PC, et al. The brain modulates insulin sensitivity in multiple tissues. Front Horm Res. 2014;42:50–58.
   PubMed Web of Science ®Google Scholar
• Routh VH, Hao L, Santiago AM, et al. Hypothalamic glucose sensing: making ends meet. Front Syst Neurosci. 2014;8:236.
   PubMedGoogle Scholar
• Picard A, Moullé VS, Le Foll C, et al. Physiological and pathophysiological implications of lipid sensing in the brain. Diabetes Obes Metab. 2014;16(Suppl1):49–55.
   PubMed Web of Science ®Google Scholar
• Martinac M, Pehar D, Karlović D, et al. Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in depressive disorder. Acta Clin Croat. 2014;53:55–71.
   PubMed Web of Science ®Google Scholar
• Bisschop PH, Fliers E, Kalsbeek A. Autonomic regulation of hepatic glucose production. Compr Physiol. 2015;5:147–165.
   PubMed Web of Science ®Google Scholar
• Jordan SD, Könner AC, Brüning JC. Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis. Cell Mol Life Sci. 2010;67:3255–3273.
   PubMed Web of Science ®Google Scholar
• Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22:423–436.
   PubMed Web of Science ®Google Scholar
• Younk LM, Lamos EM, Davis SN. The cardiovascular effects of insulin. Expert Opin Drug Saf. 2014;13:955–966.
   PubMed Web of Science ®Google Scholar
• Otero YF, Stafford JM, McGuinness OP. Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux. J Biol Chem. 2014;289:20462–20469.
   PubMed Web of Science ®Google Scholar
• Boden G, Carnell LH. Nutritional effects of fat on carbohydrate metabolism. Best Pract Res Clin Endocrinol Metab. 2003;17:399–410.
   PubMed Web of Science ®Google Scholar
• Morrison CD, Huypens P, Stewart LK, et al. Implications of crosstalk between leptin and insulin signaling during the development of diet-induced obesity. Biochim Biophys Acta. 2009;1792:409–416.
   PubMed Web of Science ®Google Scholar
• Martins AR, Nachbar RT, Gorjao R, et al. Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis. 2012;11:30.
   PubMed Web of Science ®Google Scholar
• Levin BE, Magnan C, Migrenne S, et al. F-DIO obesity-prone rat is insulin resistant before obesity onset. Am J Physiol Regul Integr Comp Physiol. 2005;289:R704–11.
   PubMed Web of Science ®Google Scholar
• Zimmet PZ. Challenges in diabetes epidemiology – from west to the rest. Diabetes Care. 1992;232:252.
   Google Scholar
• Dowse G, Zimmet P. The thrifty genotype in non-insulin dependent diabetes. BMJ. 1993;306:532–533.
   PubMed Web of Science ®Google Scholar
• Popkin BM, Slining MM. New dynamics in global obesity facing low- and middle-income countries. Obes Rev. 2013;14(Suppl2):11–20.
   PubMed Web of Science ®Google Scholar
• Rivellese AA, De Natale C, Lilli S. Type of dietary fat and insulin resistance. Ann N Y Acad Sci. 2002;967:329–335.
   PubMed Web of Science ®Google Scholar
• Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr. 2004;23:447–456.
   PubMed Web of Science ®Google Scholar
• Levin BE, Dunn-Meynell AA, Balkan B, et al. Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol. 1997;273:R725–30.
   PubMed Web of Science ®Google Scholar
• Heitmann BL, Westerterp KR, Loos RJ, et al. Obesity: lessons from evolution and the environment. Obes Rev. 2012;13:910–922.
   PubMed Web of Science ®Google Scholar
• Singh RB, Gupta S, Dherange P, et al. Metabolic syndrome: a brain disease. Can J Physiol Pharmacol. 2012;90:1171–1183.
   PubMed Web of Science ®Google Scholar
• Biebermann H, Kühnen P, Kleinau G, et al. The neuroendocrine circuitry controlled by POMC, MSH, and AGRP. Handb Exp Pharmacol. 2012;209:47–75.
   PubMedGoogle Scholar
• Ellacott KL, Cone RD. The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Prog Horm Res. 2004;59:395–408.
   PubMedGoogle Scholar
• Fani L, Bak S, Delhanty P, et al. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Int J Obes (Lond). 2014;38:163–169.
   PubMed Web of Science ®Google Scholar
• Baltatzi M, Hatzitolios A, Tziomalos K, et al. Neuropeptide Y and alpha-melanocyte-stimulating hormone: interaction in obesity and possible role in the development of hypertension. Int J Clin Pract. 2008;62:1432–1440.
   PubMed Web of Science ®Google Scholar
• Cone RD, Cowley MA, Butler AA, et al. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord. 2001;25(Suppl5):S63–7.
   PubMed Web of Science ®Google Scholar
• Belgardt BF, Okamura T, Brüning JC. Hormone and glucose signalling in POMC and AgRP neurons. J Physiol. 2009;587:5305–5314.
   PubMed Web of Science ®Google Scholar
• Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab. 2004;15:362–369.
   PubMed Web of Science ®Google Scholar
• Leinninger GM. Lateral thinking about leptin: a review of leptin action via the lateral hypothalamus. Physiol Behav. 2011;104:572–581.
   PubMed Web of Science ®Google Scholar
• Opland DM, Leinninger GM, Myers MG Jr. Modulation of the mesolimbic dopamine system by leptin. Brain Res. 2010;1350:65–70.
   PubMed Web of Science ®Google Scholar
• Van Zessen R, Van Der Plasse G, Adan RA. Contribution of the mesolimbic dopamine system in mediating the effects of leptin and ghrelin on feeding. Proc Nutr Soc. 2012;71:435–445.
   PubMed Web of Science ®Google Scholar
• Bingham NC, Anderson KK, Reuter AL, et al. Selective loss of leptin receptors in the ventromedial hypothalamic nucleus results in increased adiposity and a metabolic syndrome. Endocrinology. 2008;149:2138–2148
   PubMed Web of Science ®Google Scholar
• Irani BG, Le Foll C, Dunn-Meynell AA, et al. Ventromedial nucleus neurons are less sensitive to leptin excitation in rats bred to develop diet-induced obesity. Am J Physiol Regul Integr Comp Physiol. 2009;296:R521–7.
   PubMed Web of Science ®Google Scholar
• Toda C, Shiuchi T, Kageyama H, et al. Extracellular signal-regulated kinase in the ventromedial hypothalamus mediates leptin-induced glucose uptake in red-type skeletal muscle. Diabetes. 2013;62:2295–2307.
   PubMed Web of Science ®Google Scholar
• Toda C, Shiuchi T, Lee S, et al. Distinct effects of leptin and a melanocortin receptor agonist injected into medial hypothalamic nuclei on glucose uptake in peripheral tissues. Diabetes. 2009;58:2757–2765.
   PubMed Web of Science ®Google Scholar
• Pfaffly J, Michaelides M, Wang GJ, et al. Leptin increases striatal dopamine D2 receptor binding in leptin-deficient obese (ob/ob) mice. Synapse. 2010;64:503–510.
   PubMed Web of Science ®Google Scholar
• Marino JS, Xu Y, Hill JW. Central insulin and leptin-mediated autonomic control of glucose homeostasis. Trends Endocrinol Metab. 2011;22:275–285.
   PubMed Web of Science ®Google Scholar
• Dunn JP, Kessler RM, Feurer ID, et al. Relationship of dopamine type 2 receptor binding potential with fasting neuroendocrine hormones and insulin sensitivity in human obesity. Diabetes Care. 2012;35:1105–1111.
   PubMed Web of Science ®Google Scholar
• Caravaggio F, Borlido C, Hahn M, et al. Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy non-obese humans. Int J Neuropsychopharmacol. 2015;pii:pyv014.
   Web of Science ®Google Scholar
• Meier A, Cincotta A. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev. 1996;4:464–487.
   Google Scholar
• Cincotta A. Hypothalamic role in the insulin resistance syndrome. In: Hansen B, Shaffrir E, editors. Resistance and insulin resistance syndrome. London: Taylor and Francis; 2002. p. 271–312.
   Google Scholar
• La Fleur SE. Daily rhythms in glucose metabolism: suprachiasmatic nucleus output to peripheral tissue. J Neuroendocrinol. 2003;15:315–322.
   PubMed Web of Science ®Google Scholar
• Kalsbeek A, Bruinstroop E, Yi CX, et al. Hypothalamic control of energy metabolism via the autonomic nervous system. Ann N Y Acad Sci. 2010;1212:114–129.
   PubMed Web of Science ®Google Scholar
• Bailey SM, Udoh US, Young ME. Circadian regulation of metabolism. J Endocrinol. 2014;222:R75–96.
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, Pazienza V, Vinciguerra M. Clock genes and clock-controlled genes in the regulation of metabolic rhythms. Chronobiol Int. 2012;29:227–251.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH. Circadian rhythms of lipogenic and hypoglycaemic responses to insulin in the golden hamster (Mesocricetus auratus). J Endocrinol. 1984;103:141–146.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH. Prolactin permits the expression of a circadian variation in lipogenic responsiveness to insulin in hepatocytes of the golden hamster (Mesocricetus auratus). J Endocrinol. 1985;106:173–176.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH. Prolactin permits the expression of a circadian variation in insulin receptor profile in hepatocytes of the golden hamster (Mesocricetus auratus). J Endocrinol. 1985;106:177–181.
   PubMed Web of Science ®Google Scholar
• Froy O. The relationship between nutrition and circadian rhythms in mammals. Front Neuroendocrinol. 2007;28:61–71.
   PubMed Web of Science ®Google Scholar
• Kalsbeek A, La Fleur S, Fliers E. Circadian control of glucose metabolism. Mol Metab. 2014;3:372–383.
   PubMed Web of Science ®Google Scholar
• Ramsey KM, Bass J. Circadian clocks in fuel harvesting and energy homeostasis. Cold Spring Harb Symp Quant Biol. 2011;76:63–72.
   PubMedGoogle Scholar
• Boers I, Muskiet FA, Berkelaar E, et al. Favourable effects of consuming a Palaeolithic-type diet on characteristics of the metabolic syndrome: a randomized controlled pilot-study. Lipids Health Dis. 2014;13:160.
   PubMed Web of Science ®Google Scholar
• Manheimer EW, Van Zuuren EJ, Fedorowicz Z, et al. Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis. Am J Clin Nutr. 2015;102:922–932.
   PubMed Web of Science ®Google Scholar
• Spreadbury I. Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity. Diabetes Metab Syndr Obes. 2012;5:175–189.
   PubMedGoogle Scholar
• Tsujimoto T, Yamamoto-Honda R, Kajio H, et al. Seasonal variations of severe hypoglycemia in patients with type 1 diabetes mellitus, type 2 diabetes mellitus, and non-diabetes mellitus: clinical analysis of 578 hypoglycemia cases. Medicine (Baltimore). 2014;93:e148.
   PubMed Web of Science ®Google Scholar
• Nordfeldt S, Ludvigsson J. Seasonal variation of HbA1c in intensive treatment of children with type 1 diabetes. J Pediatr Endocrinol Metab. 2000;13:529–535.
   PubMed Web of Science ®Google Scholar
• Sakura H, Tanaka Y, Iwamoto Y. Seasonal fluctuations of glycated hemoglobin levels in Japanese diabetic patients. Diabetes Res Clin Pract. 2010;88:65–70.
   PubMed Web of Science ®Google Scholar
• Liang WW. Seasonal changes in preprandial glucose, A1C, and blood pressure in diabetic patients. Diabetes Care. 2007;30:2501–2502.
   PubMed Web of Science ®Google Scholar
• Ishii H, Suzuki H, Baba T, et al. Seasonal variation of glycemic control in type 2 diabetic patients. Diabetes Care. 2001;24:1503.
   PubMed Web of Science ®Google Scholar
• Sohmiya M, Kanazawa I, Kato Y. Seasonal changes in body composition and blood HbA1c levels without weight change in male patients with type 2 diabetes treated with insulin. Diabetes Care. 2004;27:1238–1239.
   PubMed Web of Science ®Google Scholar
• Gikas A, Sotiropoulos A, Pastromas V, et al. Seasonal variation in fasting glucose and HbA1c in patients with type 2 diabetes. Prim Care Diabetes. 2009;3:111–114.
   PubMedGoogle Scholar
• Partonen T. During winter the body resists insulin. Hypertens Res. 2013;36:390–391.
   PubMed Web of Science ®Google Scholar
• Kamezaki F, Sonoda S, Nakata S, et al. Association of seasonal variation in the prevalence of metabolic syndrome with insulin resistance. Hypertens Res. 2013;36:398–402.
   PubMed Web of Science ®Google Scholar
• Kamezaki F, Sonoda S, Tomotsune Y, et al., et al. Seasonal variation in metabolic syndrome prevalence. Hypertens Res. 2010;33:568–572.
   PubMed Web of Science ®Google Scholar
• Meier AH. Temporal synergism of circadian neuroendocrine oscillations regulates seasonal conditions in the gulf killifish. Trans Am Fish Soc. 1984;113:422–431.
   Web of Science ®Google Scholar
• Meier AH, Russo AC. Circadian organization of the avian annual cycle. In: Johnston RE, editor. Current ornithology. Vol. 2. New York (NY): Plenum; 1984. p. 303–343.
   Google Scholar
• Emata AC, Meier AH, Spieler RE. Temporal variations in gonadal and body fat responses to daily injections of a 5-hydroxytryptophan (5-HTP) and dihydroxyphenylalanine (DOPA) in the gulf killifish, Fundulus grandis. J Exp Zool. 1985;233:29–34.
   Google Scholar
• Wilson JM, Meier AH. Resetting the annual cycle with timed daily injections of 5-hydroxytryptophan and L-dihydroxyphenylalanine in Syrian hamsters. Chronobiol Int. 1989;6:113–121.
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Cincotta AH. Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. Neuroreport. 1999;10:2073–2077.
   PubMed Web of Science ®Google Scholar
• Luo S, Zhang Y, Ezrokhi M, et al. High-fat feeding abolishes the insulin-sensitizing peak in circadian dopamine activity at the biological clock. Diabetes. 2014;63(Suppl1):A470.
   Google Scholar
• Luo S, Luo J, Meier A. Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport. 1997;8:3495–3499.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Luo S, Ezrokhi M, et al. Increasing GABAa/AMPA receptor ratio stimulation at the supramammillary nucleus (SuMN) induces insulin resistance (IR) without weight gain in rats. Diabetes. 2014;63(Suppl1):A494.
   PubMed Web of Science ®Google Scholar
• Luo S, Ezrokhi M, Trubitsyna Y, et al. One minute of circadian-timed daily dopamine (DA) administration at the biological clock for 2 weeks ameliorates metabolic syndrome in spontaneously hypertensive rats (SHR) held on a high fat diet (HFD). Diabetes. 2015;64(Suppl1):A523.
   Google Scholar
• Zhang Y, Luo S, Ezrokhi M, et al. Circadian-timed daily activation of supramammillary nucleus (SuMN) ameliorates obesity/insulin resistance in high fat diet-induced insulin resistant rats. Diabetes. 2015;64(Suppl1):A536.
   Google Scholar
• Ezrokhi M, Luo S, Trubitsyna Y, et al. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr. 2014;6:104.
   PubMed Web of Science ®Google Scholar
• Luo S, Ezrokhi M, Trubitsyna Y, et al. Intrahypothalamic circuitry regulating hypothalamic fuel sensing to induce insulin sensitivity or insulin resistance. Diabetologia. 2008;51(Suppl1):S1–S588.
   PubMed Web of Science ®Google Scholar
• Pocai A, Lam TK, Obici S, et al. Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J Clin Invest. 2006;116:1081–1091.
   PubMed Web of Science ®Google Scholar
• Lam TK. Neuronal regulation of homeostasis by nutrient sensing. Nat Med. 2010;16:392–395.
   PubMed Web of Science ®Google Scholar
• Breen DM, Yang CS, Lam TK. Gut-brain signaling: how lipids can trigger the gut. Diabetes Metab Res Rev. 2011;27:113–119.
   PubMed Web of Science ®Google Scholar
• Jordan SD, Könner AC, Brüning JC. Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis. Cell Mol Life Sci. 2010;67:3255–3273.
   PubMed Web of Science ®Google Scholar
• Morgan K, Obici S, Rossetti L. Hypothalamic responses to long-chain fatty acids are nutritionally regulated. J Biol Chem. 2004;279:31139–31148.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Luo S, Zhang Y, et al. Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regulatory Integrative Comp Physiol. 2000;278:R435–R444.
   PubMed Web of Science ®Google Scholar
• Dicostanzo CA, Dardevet DP, Neal DW, et al. Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal. Am J Physiol Endocrinol Metab. 2006;290:E9–E16.
   PubMed Web of Science ®Google Scholar
• Lambert GW, Straznicky NE, Lambert EA, at al Sympathetic nervous activation in obesity and the metabolic syndrome–causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126:159–172.
   PubMed Web of Science ®Google Scholar
• Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res. 2006;29:839–847.
   PubMed Web of Science ®Google Scholar
• Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci. 2006;1083:129–152.
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology. 1999;70:460–465.
   PubMed Web of Science ®Google Scholar
• Liang Y, Luo S, Cincotta AH. Long-term infusion of norepinephrine plus serotonin into the ventromedial hypothalamus impairs pancreatic islet function. Metabolism. 1999;48:1287–1289.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Luo S, Liang Y. Hyperinsulinemia increases norepinephrine metabolism in the ventromedial hypothalamus of rats. Neuroreport. 2000;11:383–387.
   PubMed Web of Science ®Google Scholar
• Shimazu T. Neuronal regulation of hepatic glucose metabolism in mammals. Diabetes Metab Rev. 1987;3:185–206.
   PubMedGoogle Scholar
• Steffens AB, Damsma G, Vasnder Gugten J, et al. Circulating fatty acids, insulin, and glucose during chemical stimulation of hypothalamus in rats. Am J Physiol. 1984;247:E765–71.
   PubMed Web of Science ®Google Scholar
• Borg WP, Sherwin RS, During MJ, et al. Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes. 1995;44:180–184.
   PubMed Web of Science ®Google Scholar
• Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000;71:68–78.
   PubMed Web of Science ®Google Scholar
• Ferrie JE, Kivimäki M, Akbaraly TN, et al. Change in sleep duration and type 2 diabetes: the Whitehall II Study. Diabetes Care. 2015;38:1467–1472.
   PubMed Web of Science ®Google Scholar
• Vetter C, Devore EE, Ramin CA, et al. Mismatch of sleep and work timing and risk of type 2 diabetes. Diabetes Care. 2015;38:1707–1713.
   PubMed Web of Science ®Google Scholar
• Scheer FA, Hilton MF, Mantzoros CS, et al. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA. 2009;106:4453–4458.
   PubMed Web of Science ®Google Scholar
• Leproult R, Holmback U, Van Cauter E. Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss. Diabetes. 2014;63:1860–1869.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Adda G, Scillitani A, et al. Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care. 2007;30:83–88.
   PubMed Web of Science ®Google Scholar
• Farag NH, Moore WE, Lovallo WR, et al. Hypothalamic-pituitary-adrenal axis function: relative contributions of perceived stress and obesity in women. J Womens Health (Larchmt). 2008;17:1647–1655.
   PubMed Web of Science ®Google Scholar
• Jokinen J, Nordström P. HPA axis hyperactivity and attempted suicide in young adult mood disorder inpatients. J Affect Disord. 2009;116:117–120.
   PubMed Web of Science ®Google Scholar
• Mendoza J, Challet E. Circadian insights into dopamine mechanisms. Neuroscience. 2014;282C:230–242.
   PubMed Web of Science ®Google Scholar
• Argyropoulos SV, Nutt DJ. Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? J Psychopharmacol. 2013;27:869–877.
   PubMed Web of Science ®Google Scholar
• Lim BK, Huang KW, Grueter BA, et al. Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens. Nature. 2012 Jul 11;487(7406):183–189.
   PubMed Web of Science ®Google Scholar
• Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev. 2007;11:113–133.
   PubMed Web of Science ®Google Scholar
• Geiger BM, Haburcak M, Avena NM, et al. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience. 2009;159:1193–1199.
   PubMed Web of Science ®Google Scholar
• Davis JF, Tracy AL, Schurdak JD, et al. Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat. Behav Neurosci. 2008;122:1257–1263.
   PubMed Web of Science ®Google Scholar
• Rada P, Bocarsly ME, Barson JR, et al. Reduced accumbens dopamine in Sprague-Dawley rats prone to overeating a fat-rich diet. Physiol Behav. 2010;101:394–400.
   PubMed Web of Science ®Google Scholar
• Geiger BM, Behr GG, Frank LE, et al. Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats. FASEB J. 2008;22:2740–2746.
   PubMed Web of Science ®Google Scholar
• Blum K, Chen TJ, Downs BW, et al. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing “deprivation-amplification relapse therapy” (DART). Postgrad Med. 2009;121:176–196.
   PubMed Web of Science ®Google Scholar
• Noble EP. Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. Eur Psychiatry. 2000;15:79–89.
   PubMed Web of Science ®Google Scholar
• Billes SK, Simonds SE, Cowley MA. Leptin reduces food intake via a dopamine D2 receptor-dependent mechanism. Mol Metab. 2012;1:86–93.
   PubMed Web of Science ®Google Scholar
• Zheng H, Liu X, Li Y, et al. Attenuated dopaminergic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with Type 2 diabetes. Am J Physiol Regul Integr Comp Physiol. 2014;306:R138–48.
   PubMed Web of Science ®Google Scholar
• Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology. 1998;68:1–10.
   PubMed Web of Science ®Google Scholar
• Ezrokhi M, Luo S, Trubitsyna Y, et al. Weighted effects of bromocriptine treatment on glucose homeostasis during hyperglycemic versus euglycemic clamp conditions in insulin resistant hamsters: bromocriptine as a unique postprandial insulin sensitizer. J Diabetes Metab. 2012;S2:7.
   Google Scholar
• Moore MC, Smith M, Farmer B, et al. Timed daily bromocriptine mesylate (BC) administration improves glucose disposal in a canine diet-induced model of impaired glucose tolerance. Diabetologia. 2014;57(Suppl1):S350.
   Google Scholar
• Cincotta AH, Schiller BC, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism. 1991;40:639–644.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, MacEachern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol. 1993;264:E285–93.
   PubMed Web of Science ®Google Scholar
• Scislowski PW, Tozzo E, Zhang Y, et al. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord. 1999;23:425–431.
   PubMed Web of Science ®Google Scholar
• Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology. 1999;69:160–166.
   PubMed Web of Science ®Google Scholar
• Davis LM, Pei Z, Trush MA, et al. Bromocriptine reduces steatosis in obese rodent models. J Hepatol. 2006;45:439–444.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH, Southern LL. Bromocriptine alters hormone rhythms and lipid metabolism in swine. Ann Nutr Metab. 1989;33:305–314.
   PubMed Web of Science ®Google Scholar
• Ezrokhi M, Luo S, Trubitsyna T, et al. Synergism of dopamine agonist plus GLP-1 analog therapy on improvement of glucose intolerance in Syrian hamsters. Diabetes. 2011;60(Suppl1):A445.
   Google Scholar
• Cincotta AH, Schiller BC, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism. 1991;40:639–644.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH. Prolactin permits the expression of a circadian variation in lipogenic responsiveness to insulin in hepatocytes of the golden hamster (Mesocricetus auratus). J Endocrinol. 1985;106:173–176.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism. 1995;44:1349–1355.
   PubMed Web of Science ®Google Scholar
• Liang Y, Jetton TL, Lubkin M, et al. Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell Mol Life Sci. 1998;54:703–711.
   PubMed Web of Science ®Google Scholar
• Ezrokhi M, Trubitsyna Y, Luo S, et al. Timed dopamine agonist treatment ameliorates both vascular nitrosative/oxidative stress pathology and aortic stiffness in arteriosclerotic, hypertensive SHR rats. Diabetes. 2010;59(Suppl1):A67.
   Google Scholar
• Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab. 2012;302:E481–95.
   PubMed Web of Science ®Google Scholar
• Santilli F, Cipollone F, Mezzetti A, et al. The role of nitric oxide in the development of diabetic angiopathy. Horm Metab Res. 2004;36:319–335.
   PubMed Web of Science ®Google Scholar
• Magenta A, Greco S, Capogrossi MC, et al. Nitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunction. Biomed Res Int. 2014;2014:193095.
   PubMed Web of Science ®Google Scholar
• Narkar V, Kunduzova O, Hussain T, et al. Dopamine D2-like receptor agonist bromocriptine protects against ischemia/reperfusion injury in rat kidney. Kidney Int. 2004;66:633–640.
   PubMed Web of Science ®Google Scholar
• Gao J, Guo J, Li H, et al. Involvement of dopamine D2 receptors activation in ischemic post-conditioning-induced cardioprotection through promoting PKC-ε particulate translocation in isolated rat hearts. Mol Cell Biochem. 2013;379:267–276.
   PubMed Web of Science ®Google Scholar
• Li HZ, Guo J, Gao J, et al. Role of dopamine D2 receptors in ischemia/reperfusion induced apoptosis of cultured neonatal rat cardiomyocytes. J Biomed Sci. 2011;18:18.
   PubMed Web of Science ®Google Scholar
• Cycloset^® [package insert]. Tiverton (RI): VeroScience LLC;2010 9.
   Google Scholar
• Park S, Kang S, Lee HW, et al. Central prolactin modulates insulin sensitivity and insulin secretion in diabetic rats. Neuroendocrinology. 2012;95:332–343.
   PubMed Web of Science ®Google Scholar
• Ferrari E, Bossolo P, Marelli G, et al. Hormonal circadian profiles in obesity. Annu Rev Chronopharmacol. 1986;3:99–402.
   Google Scholar
• Cupinschi G, DeLaet MH, Brion JP, et al. Simultaneous study of cortisol, growth hormone, and prolactin nyctohemeral variations in normal and obese subjects: influence of prolonged fasting in obesity. Clin Endocrinol. 1978;9:15–26.
   PubMed Web of Science ®Google Scholar
• Ferrari E, Magri F, Dori D. Neuroendocrine abnormalities in primary obesity. In: Ferrari E, Brambilla F, Solerte SB, et al., editors. Primary and secondary eating disorders: a psychoneuroendocrine and metabolic approach. Vol. 90, Oxford (UK): Pergamon; 1993. p. 287.
   Google Scholar
• Kok P, Roelfsema F, Frölich M, et al. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab. 2004;89:4445–4449.
   PubMed Web of Science ®Google Scholar
• Kok P, Roelfsema F, Langendonk JG, et al. Increased circadian prolactin release is blunted after body weight loss in obese premenopausal women. Am J Physiol Endocrinol Metab. 2006;290:E218–24.
   PubMed Web of Science ®Google Scholar
• Berinder K, Nyström T, Höybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14:199–207.
   PubMed Web of Science ®Google Scholar
• Tuzcu A, Yalaki S, Arikan S, et al. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary. 2009;12:330–334.
   PubMed Web of Science ®Google Scholar
• Tuzcu A, Bahceci M, Dursun M, et al. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 2003;26:341–346.
   PubMed Web of Science ®Google Scholar
• Foss MC, Paula FJ, Paccola GM, et al. Peripheral glucose metabolism in human hyperprolactinaemia. Clin Endocrinol (Oxf). 1995;43:721–726.
   PubMed Web of Science ®Google Scholar
• Serri O, Beauregard H, Rasio E, et al. Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril. 1986;45:572–574.
   PubMed Web of Science ®Google Scholar
• Dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19:800–805.
   PubMed Web of Science ®Google Scholar
• Landgraf R, Landraf-Leurs MM, Weissmann A, et al. Prolactin: a diabetogenic hormone. Diabetologia. 1977;13:99–104.
   PubMed Web of Science ®Google Scholar
• Johnston DG, Alberti KG, Nattrass M, et al. Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf). 1980;13:361–368.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH, Taylor E, et al. Bromocriptine (Ergoset) reduces body fat, hyperinsulinemia and glucose intolerance in obese subjects. Diabetes. 1995;44(Suppl.1):168A.
   Google Scholar
• Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999;8:1683–1707.
   PubMedGoogle Scholar
• Scranton R, Cincotta A. Bromocriptine–unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11:269–279.
   PubMed Web of Science ®Google Scholar
• Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154–1161.
   PubMed Web of Science ®Google Scholar
• Mancia G, Bousquest P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25:909–920.
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Kok P, Pereira AM, et al. Cortisol production rate is similarly elevated in obese women with or without the polycystic ovary syndrome. J Clin Endocrinol Metab. 2010;95:3318–3324.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Ezrokhi M, Trubitsyna Y, et al. Lesion of dopaminergic afferent neurons communicating with the biological clock induces metabolic syndrome in rats. Diabetes. 2015;64(Suppl1):A540.
   Google Scholar
• Geerling JJ, Boon MR, Kooijman S, et al. Sympathetic nervous system control of triglyceride metabolism: novel concepts derived from recent studies. J Lipid Res. 2014;55:180–189.
   PubMed Web of Science ®Google Scholar
• Straznicky NE, Lambert EA, Lambert GW, et al. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab. 2005;90:5998–6005.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, et al. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Ezrokhi M. The anti-diabetes efficacy of Bromocriptine-QR in type 2 diabetes mellitus (T2DM) subjects is enhanced among those with elevated blood pressure and plasma triglyceride levels. Diabetes. 2013;62(Suppl1):A305.
   Google Scholar
• Cincotta AH, Meier AH. Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment. Life Sci. 1989;45:2247–2254.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Cincotta AH, Scranton RE, et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18:931–943.
   PubMed Web of Science ®Google Scholar
• Scranton RE, Gaziano JM, Rutty D, et al. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord. 2007;7:3.
   PubMedGoogle Scholar
• Florez H, Scranton R, Farwell WR, et al. Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J Diabetes Metab. 2011;2:142.
   Google Scholar
• Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci. 2000;21:469–474.
   PubMed Web of Science ®Google Scholar
• Zeender E, Maedler K, Bosco D, et al. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab. 2004;89:5059–5066.
   PubMed Web of Science ®Google Scholar
• Diani AR, Sawada G, Wyse B, et al. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004;286:E116–22.
   PubMed Web of Science ®Google Scholar
• Schwartz S. Bromocriptine (Ergoset) improves glycemic control in type 2 diabetics on insulin. Diabetes. 1999;48(Suppl1):A99.
   PubMed Web of Science ®Google Scholar
• Roe ED, Chamarthi B, Raskin P. Impact of bromocriptine-QR therapy on glycemic control and daily insulin requirement in type 2 diabetes mellitus subjects whose dysglycemia is poorly controlled on high-dose insulin: a pilot study. J Diabetes Res. 2015;2015:834903.
   PubMed Web of Science ®Google Scholar
• Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci. 2010;1212:29–40.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002;288:2579–2588.
   PubMed Web of Science ®Google Scholar
• Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res. 2006;29:839–847.
   PubMed Web of Science ®Google Scholar
• Lambert GW, Straznicky NE, Lambert EA, et al. Sympathetic nervous activation in obesity and the metabolic syndrome–causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126:159–172.
   PubMed Web of Science ®Google Scholar
• Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci. 2006;1083:129–152.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Cincotta AH, O’Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33:1503–1508.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Cincotta AH, Vinik A, et al. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1:e002279.
   PubMed Web of Science ®Google Scholar
• Chamarthi B, Gaziano JM, Blonde L, et al. Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:157698.
   PubMed Web of Science ®Google Scholar
• Halberg F, Powell D, Otsuka K, et al. Diagnosing vascular variability anomalies, not only MESOR-hypertension. Am J Physiol Heart Circ Physiol. 2013;305:H279–94.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernandez JR, et al. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int. 2013;30:280–314.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Mazzotta G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension. 2012;60:34–42.
   PubMed Web of Science ®Google Scholar
• Kanth R, Ittaman S, Rezkalla S. Circadian patterns of ST elevation myocardial infarction in the new millennium. Clin Med Res. 2013;11:66–72.
   PubMedGoogle Scholar
• Giles TD. Circadian rhythm of blood pressure and the relation to cardiovascular events. J Hypertens Suppl. 2006;24:S11–6.
   PubMedGoogle Scholar
• Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733–743.
   PubMed Web of Science ®Google Scholar
• Senard JM, Rai S, Lapeyre-Mestre M, et al. JL. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63:584–589.
   PubMed Web of Science ®Google Scholar
• Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord. 2009;24:129–133.
   PubMed Web of Science ®Google Scholar
• Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6:826–829.
   PubMed Web of Science ®Google Scholar
• Kim JY, Chung EJ, Park SW, et al. Valvular heart disease in Parkinson’s disease treated with ergot derivative dopamine agonists. Mov Disord. 2006;21:1261–1264.
   PubMed Web of Science ®Google Scholar
• Tan LC, Ng KK, Au WL, et al. Bromocriptine use and the risk of valvular heart disease. Mov Disord. 2009;24:344–349.
   PubMed Web of Science ®Google Scholar
• Halperin I, Aller J, Varela C, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol. 2012;77:275–280.
   PubMed Web of Science ®Google Scholar
• Elenkova A, Shabani R, Kalinov K, et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012;167:17–25.
   PubMed Web of Science ®Google Scholar
• Boguszewski CL, Dos Santos CM, Sakamoto KS, et al. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012;15:44–49.
   PubMed Web of Science ®Google Scholar
• Drake WM, Stiles CE, Howlett TA, et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014;99:90–96.
   PubMed Web of Science ®Google Scholar
• Liang W, Gao L, Li N, et al. Efficacy and safety of bromocriptine-QR in type 2 diabetes: a systematic review and meta-analysis. Horm Metab Res. 2015;47:805–812.
   PubMed Web of Science ®Google Scholar
• Kalsbeek A, Scheer FA, Perreau-Lenz S, et al. Circadian disruption and SCN control of energy metabolism. FEBS Lett. 2011;585:1412–1426.
   PubMed Web of Science ®Google Scholar
• Reutrakul S, Van Cauter E. Interactions between sleep, circadian function, and glucose metabolism: implications for risk and severity of diabetes. Ann N Y Acad Sci. 2014;1311:151–173.
   PubMed Web of Science ®Google Scholar
• Cipolla-Neto J, Amaral FG, Afeche SC, et al. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014;56:371–381.
   PubMed Web of Science ®Google Scholar
• Antunes LC, Levandovski R, Dantas G, et al. Obesity and shift work: chronobiological aspects. Nutr Res Rev. 2010;23:155–168.
   PubMed Web of Science ®Google Scholar
• Steylen PM, Van Der Heijden FM, Hoogendijk WJ, et al. Glycosylated hemoglobin as a screening test for hyperglycemia in antipsychotic-treated patients: a follow-up study. Diabetes Metab Syndr Obes. 2015;8:57–63.
   PubMed Web of Science ®Google Scholar
• Musil R, Obermeier M, Russ P, et al. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14:73–96.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacol Ther. 2010;125:169–179.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl1):1–93.
   PubMed Web of Science ®Google Scholar
• Mallis MM, DeRoshia CW. Circadian rhythms, sleep, and performance in space. Aviat Space Environ Med. 2005;76(6Suppl):B94–107.
   PubMedGoogle Scholar